

# 1 Exploration of wastewater surveillance for Monkeypox virus

2  
3 Edgard M Mejia<sup>1,#</sup>, Nikho A Hizon<sup>1,#</sup>, Codey E Dueck<sup>1</sup>, Ravinder Lidder<sup>1</sup>, Jade Daigle<sup>1</sup>, Quinn  
4 Wonitowy<sup>1</sup>, Nestor G Medina<sup>1</sup>, Umar P Mohammed<sup>1</sup>, Graham W Cox<sup>1</sup>, David Safronetz<sup>2,4</sup>,  
5 Mable Hagan<sup>2</sup>, Jim Strong<sup>2,4</sup>, Anil Nichani<sup>1</sup>, Michael R Mulvey<sup>1,3,4</sup> and Chand S Mangat<sup>1,3,4\*</sup>

6  
7 <sup>1</sup>Wastewater Surveillance Unit, One Health Division, National Microbiology Laboratory, Public  
8 Health Agency of Canada, Winnipeg, Canada

9 <sup>2</sup>Special Pathogens Section, National Microbiology Laboratory, Public Health Agency of  
10 Canada, Winnipeg, Canada

11 <sup>3</sup>Antimicrobial Resistance Nosocomial Infections, National Microbiology Laboratory, Public  
12 Health Agency of Canada, Winnipeg, Canada

13 <sup>4</sup>Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine,  
14 Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada

15  
16 \*Corresponding Author: Chand S. Mangat, One Health Division, National Microbiology  
17 Laboratory, Public Health Agency of Canada.

18 #These authors contributed equally to this work.

19 Address: JC Wilt Infectious Diseases Research Centre

20 745 Logan Ave

21 Winnipeg, MB, Canada

22 R3E 3L5

23 Email: [chand.mangat@phac-aspc.gc.ca](mailto:chand.mangat@phac-aspc.gc.ca), Tel: 204-789-6506, Fax: 204-789-5020

24 **Key words:** Monkeypox, wastewater, real-time qPCR

25 **Running title:** Detection of Monkeypox in Canadian wastewater

## 30 **Abstract**

31

32         The sudden emergence and spread of Monkeypox in non-endemic parts of the  
33 world is currently not well understood. Infections are often mis-diagnosed and  
34 surveillance strategies are scarce. Wastewater-based surveillance (WBS) of human  
35 Monkeypox virus (MPXV) can help supplement our current clinical surveillance and  
36 mitigation efforts. WBS has shown to be an effective tool in monitoring the spread of  
37 other infectious pathogens, such as SARS-CoV-2 and its variants, and has helped  
38 guide public health actions. In this study, we describe how WBS can be used to detect  
39 MPXV in wastewater. We conducted WBS for MPXV in 22 wastewater treatment plants  
40 (WWTPs) over a period of 14 weeks. Nucleic acids were extracted using the  
41 MagAttract PowerMicrobiome DNA/RNA extraction kit. Three real-time qPCR assays  
42 were assessed for the detection of MPXV in wastewater. These included the G2R  
43 assays (G2R\_WA and G2R\_G) developed by the Centers for Disease Control and  
44 Prevention (CDC) in 2010, as well as an in-house-developed assay (G2R\_NML). The  
45 G2R\_G (generic) assay was designed to detect both the Congo and West African  
46 clades (re-named to Clades one and two, respectively) of viruses while the G2R\_WA  
47 assay was designed to detect the West African clade (Clade one). The G2R\_NML  
48 assay was designed using reference genomes of the 2022 MPXV outbreak. Our results  
49 show that all three assays have similar limits of detection and are all able to detect the  
50 presence of MPXV in wastewater. Following detection through real time qPCR, Sanger  
51 sequencing was performed on the resulting amplicon products, with the assembled  
52 contigs then undergoing analysis using nucleotide Basic Local Alignment Search Tool  
53 (BLAST). Due in part to the longer amplicon size of the G2R\_NML assay, a significantly  
54 greater number of positive detections were identified as originating from MPXV  
55 compared to the CDC G2R assays. The ability to detect trace amounts of MPXV in  
56 wastewater as well as obtain Sanger sequence confirmation, has allowed for the  
57 successful surveillance of this virus in wastewater.

58

59

## 60 Introduction

61

62 The WHO has declared the current Monkeypox (MPXV) outbreak as a Public  
63 Health Emergency of International Concern<sup>1</sup>. As of the writing of this report, 61,827  
64 cases have been reported in 97 countries that are largely non-endemic for this disease<sup>2</sup>.  
65 MPXV was first identified in nonhuman primates in 1958 in a research setting<sup>3</sup>, and the  
66 first human clinical case was identified in 1970 in the former province of Équateur,  
67 which is now known as the Democratic Republic of the Congo<sup>4</sup>. The first clinical case  
68 was later confirmed by serological investigation as MPXV<sup>5</sup>. Cases have since been  
69 generally well controlled and limited to the central west African region. Additional cases  
70 have been reported outside of this region in the UK, Israel and Singapore, with a  
71 notable 2003 outbreak linked to pet prairie dogs in the US<sup>6</sup>.

72 MPXV is a member of the Poxviridae family of DNA viruses, the Orthopoxviridae genus  
73 to which it belongs includes smallpox and whose waning global acquired immunity has  
74 been implicated in its spread<sup>7,8</sup>. Small mammals and primates are implicated as the  
75 hosts for MPXV and the natural reservoir is undefined<sup>9</sup>. MPXV has been detected in  
76 pox lesions, the upper respiratory tract, blood, urine, feces, and semen in infected  
77 individuals linked to the 2022 outbreak<sup>10,11</sup>.

78 The virus contains a 197 kb double stranded DNA genome packaged into a 200 x 250  
79 nm virion that is described as “brick-like”<sup>7,12</sup>. MPXV is currently divided into three  
80 clades<sup>12,13</sup>; clade 1 (formerly Congo Basin clade) is typified by increased transmissibility  
81 and a higher case fatality ratio<sup>14</sup>. Clade 2 (formerly West African clade) tends to cause  
82 a milder disease and exhibits reduced transmissibility<sup>15</sup>. Isolates from the recent 2017  
83 to 2019 outbreaks form the foundation for clade 3 and include cases from the on-going  
84 2022 multi-country outbreak.

85 Molecular detection of MPXV by PCR has been elaborated in several studies describing  
86 assays that are genus, species, or clade specific<sup>16–20</sup>. The National Microbiology  
87 Laboratory, Canada’s national public health high-containment facility, supported clinical  
88 diagnosis of MPXV via four diagnostic assays; the B6R<sup>16</sup> assay and G2R\_G<sup>18</sup> assays  
89 are species-specific assays directed at the envelope protein and TNF receptor,

90 respectively. The G2R\_WA<sup>18</sup> assay is also directed at the TNF receptor gene and is  
91 specific to the clade 2 and 3, while the C3L<sup>18</sup> assay is directed at the complement  
92 binding protein and is specific to the clade 1.

93 Limited testing, a wide range of disease presentation and stigmatized transmission  
94 amongst men who have sex with men (MSM)<sup>10,11,21,22</sup> has likely increased the global  
95 spread of MPXV and alternate strategies are required to monitor the global spread of  
96 MPXV to prioritize infection control practices. Since the first detection of SARS-CoV-2  
97 in sewage<sup>23</sup>, wastewater-based epidemiology has been an effective means to provide  
98 early-warning and trending of COVID-19 in congregant living settings, small and large  
99 communities that have been communicated in hundreds of articles too numerous to  
100 provide here. The multiple shedding routes of MPXV, including stool shedding, present  
101 an opportunity to apply WBS to current MPXV outbreak. In this work, we compare the  
102 performance of the previously described G2R\_WA and G2R\_G assay described by Li  
103 and co-workers<sup>18</sup> with a novel assay named G2R\_NML. We then apply this assay to  
104 demonstrate through limited surveillance across various Canadian cities that signal  
105 derived from both these assays provide public health value by providing forewarning on  
106 the appearance of clinical cases.

107

## 108 **Materials and Methods**

109

### 110 *Sewage sample collection*

111

112 Influent 24 hr-composite wastewater samples were collected from 10 anonymized  
113 Canadian cities with collection dates ranging from June 28 to September 30th, 2022.  
114 Some 22 wastewater treatment plants were included in the study, where a major  
115 metropolitan center in 9 of 10 Canada's provinces, one province was represented by  
116 two cities. Population coverages for each province ranged between 21% to 57%  
117 (median coverage of 22 %), some 23% of all Canadians were represented in this study.  
118 Typically for most sites, two sewage samples were processed weekly from all locations.  
119 Flow data was also collected from these six communities. Samples were collected in  
120 sterile 500 mL polyethylene terephthalate (PET) bottles and were shipped to the

121 National Microbiology Laboratory at 4°C. Samples were stored at 4°C in the dark until  
122 and processed within two days of receipt (Figure 1).

123

### 124 *Sample processing and nucleic acid isolation*

125

126 We had initially attempted to survey for the MPXV signatures in wastewater in two epi-  
127 centers of the infections over the period of May through June 2022 and were unable to  
128 garner any signal (Data not shown). Briefly, the assay conditions were to extract either  
129 the insoluble material evolved from centrifugation of 30 mL of raw wastewater, or,  
130 through concentration of 15 mL of wastewater using a 10 kDa centrifugal filter device.  
131 In both cases nucleic acid was extracted using the Roche MP96 extraction platform  
132 using the DNA and Viral NA Large Volume extraction kit and detection using the  
133 G2R\_WA assay described by Li and co-workers. Only when we increased the  
134 processed volume to 200 mL and used the Qiagen PowerMicrobiome extraction kit  
135 were we able to detect MPXV in Canadian wastewater. This change was inspired by a  
136 social media post from Dr. Alexandria Boehm's group reporting on positive detections of  
137 MPXV in California and most recently reported as a pre-print using a method targeting  
138 the settled solids of wastewater. The group has since published a pre-print article<sup>24</sup> that  
139 states that MPXV is present 10<sup>3</sup> times more in the insoluble vs soluble fraction of  
140 wastewater, which is supported by the work presented here.

141 A 200 mL sample of well-mixed primary influent was centrifuged for 30 min at 12,000 x  
142 g at 4°C to yield a pellet mass that was used for subsequent processing. Nucleic acids  
143 were isolated from the wastewater solids using the MagAttract PowerMicrobiome  
144 DNA/RNA extraction kit (Qiagen, Hilden, Germany) on the Kingfisher Flex  
145 (ThermoFisher Scientific, Waltham, MA). The pellets were re-suspended in 650 µL of  
146 heated MBL solution containing 2.5% 2-mercaptoethanol and transferred to a 2 mL  
147 PowerBead Pro tube (Qiagen, Hilden, Germany). Individual bead beating tubes were  
148 chosen over the plate format to improve lysis and recovery<sup>25</sup>. The pellet-bead mixture  
149 was processed using a Bead Mill 24 Homogenizer (Fisher Scientific, Ottawa, ON) at 6  
150 m/s for three 60 s cycles with a 10 s rest. Manufacturers' recommendations were

151 followed after sample lysis with the addition of 2 uL of  $\geq 9$  mg/mL carrier RNA to each  
152 well (Sigma-Aldrich, Oakville, ON). The median effective sample volume was 128.6 mL  
153 due to lysate produced in excess of the maximum loading volume (450 uL).

154

### 155 *Real-time qPCR assay development and validation*

156

157 Primers and probes (Table 1) for the G2R\_NML real-time qPCR assay were developed  
158 *in silico* using PrimerQuest™ Tool from Integrated DNA Technologies (IDT). The target  
159 gene for this assay is the MPXV G2R gene (1050 bp in length) on the MPXVgp190  
160 locus of the Clade 2 viral genome. Using GenBank, we obtained the first complete  
161 MPXV genome sequence (MPXV\_USA\_2022\_MA001; accession ON563414) of the  
162 current 2022 MPXV outbreak and used it as a reference genome to develop the  
163 G2R\_NML assay. To determine assay specificity, the primers and probes were run  
164 through NCBI BLAST. Additionally, utilizing the GISAID genome database, we obtained  
165 supplementary MPXV genomes from the current outbreak and used them as reference  
166 genomes to determine the specificity (*in silico*) of the G2R\_NML assay. Additionally,  
167 we tested the MPXV qPCR assays developed by Li et al<sup>18</sup> and compared their  
168 performance to the G2R\_NML assay.

169

### 170 *Real-time qPCR*

171

172 Primer and probe sequences are shown in Table 1. Assay conditions for the three  
173 MPXV qPCR assays were as follows: qPCR was performed in a reaction volume of 20  
174  $\mu$ L, consisting of 5  $\mu$ L QuantiNova Multiplex PCR Kit (Qiagen, Hilden, Germany), 400  
175 nM (G2R\_G, G2R\_WA) and 300 nM (G2R\_NML) final concentration of each respective  
176 primer set (ThermoFisher Scientific); 200 nM (G2R\_G, G2R\_WA) and 250 nM  
177 (G2R\_NML) of each probe (ThermoFisher Scientific); and 5  $\mu$ L of template DNA and  
178 Invitrogen nuclease-free H<sub>2</sub>O (ThermoFisher Scientific). PCR amplification and  
179 detection of amplification products was performed on a QuantStudio 5 Real-time PCR  
180 instrument (ThermoFisher Scientific). Thermal cycling conditions were as follows:

181 polymerase activation at 95°C for 2 min, followed by 40 cycles of 95°C for 5 s and 60°C  
182 for 30 s. Each real-time PCR was performed in triplicate with the appropriate non-  
183 template controls and positive controls. Results were considered positive if they had a  
184 Ct value <40 (25). A standard curve was prepared for each target by preparing a five-  
185 point serial dilution (50,000 – 5 cp/rxn) of linearized plasmid containing the plasmid  
186 sequence (ThermoFisher) (Table 2) with nuclease-free water and qPCR was run in  
187 triplicate for each point.

188

### 189 *Assay Sensitivity*

190 Standard reference material in the form of synthetic DNA fragments were created  
191 (ThermoFisher Scientific) to support assay development and evaluation and were  
192 designed against G2R\_G, G2R\_WA, and G2R\_NML target regions (Table 2). The  
193 three MPXV standards consisted of 200 bp regions unique to the primer probe sets,  
194 which were inserted into individual pMA-RQ (AmpR) GeneArt cloning vectors  
195 (ThermoFisher Scientific). These plasmids were linearized using a high-fidelity Scal  
196 restriction enzyme (New England BioLabs) and were purified using the QIAquick PCR  
197 Purification Kit (Qiagen). TapeStation DNA ScreenTape (Agilent) was run on the  
198 plasmid constructs to confirm linearity. Standards were quantified using the Absolute  
199 Q™ Digital PCR System (ThermoFisher) following manufacturers' recommendations.

200 Assay limits of detection (ALOD)<sup>26</sup> were determined by measuring the relationship  
201 between positivity rates of standardized qPCR reactions across a 13 point serial dilution  
202 of standard reference material (as described above, see Table 2) from 45  
203 copies/reaction (cp/rxn) to 0.1 cp/rxn. For each reference material concentration, 20  
204 replicates were performed and a Ct value of < 40 was deemed to be a positive  
205 detection. A Probit model was fit to positivity rates for each assay and the ALOD was  
206 determined from where the regression model intersected with a 95% positivity rate. The  
207 ALOD confidence interval was estimated from where the regression model's confidence  
208 interval intersected at the 95% assay positivity. The Assay Limit of Quantification  
209 (ALOQ)<sup>26</sup> was determined by measuring the relationship between the coefficient of  
210 variance of standardized qPCR reactions across an 11 point serial dilution of standard

211 reference material from 45 to 3.95 cp/rxn. Reaction positivity and standard reference  
212 material are as described above. Coefficient of variation (CV) was calculated according  
213 to equation below.

$$214 \quad CV = \sqrt{1 + E \sigma_{Cq}^2 * \ln(1+E)} - 1$$

215 Where E is the PCR efficiency as described above,  $\sigma_{Cq}^2$  is the Cq standard deviation of  
216 the cycle thresholds corresponding to a specific concentration. The CV for each assay  
217 was fit to a linear regression model against the  $\log_{10}$  cp/rxn and the determined CV for  
218 each reaction. The ALOQ was where the line of best fit intersected with a CV of 35%.

219 The sample limit of detection<sup>26</sup> (SLOD) and sample limit of quantification<sup>26</sup> (SLOQ) was  
220 calculated using the median effective sample volume, template volume, and extraction  
221 volume (100  $\mu$ L) – see also<sup>27</sup> .

222

### 223 *Sanger sequencing of real-time qPCR products*

224

225 Triplicate qPCR amplification products were pooled into a total volume of 60  $\mu$ L. Pooled  
226 amplicons were purified using Ampure XP Reagent (Beckman Coulter catalog number:  
227 A63881) following the manufacturers' instructions, with a modified elution volume of 20  
228  $\mu$ L. A volume of 1  $\mu$ L of purified amplicon was Sanger-sequenced using BigDye-  
229 Terminator<sup>TM</sup> v3.1 Cycle Sequencing Reaction Kit on a 3730 xl Genetic Analyzer  
230 (Applied Biosystems, Foster City, CA, USA) following the manufacturer's instructions.  
231 PCR sequences were aligned using the Seqman Pro15 assembly program as part of  
232 the DNASTAR Lasergene 15 software suite. Assembled contigs were analyzed with  
233 nucleotide Basic Alignment Search Tool (BLAST) assigned to megablast optimization  
234 for highly similar sequences. Query results were analyzed for top matches related to  
235 Monkeypox specific query results with equal to or greater than 95% bp query coverage  
236 and equal to or greater than 95% identification.

### 237 *Clinical case data*

238



239 First case reported dates were gathered from an online web-portal  
240 <https://www.canada.ca/en/public-health/services/diseases/monkeypox.html>.

## 241 **Results**

242  
243 To augment the complement of qPCR assays to address the emerging MPXV  
244 outbreak, a qPCR assay was designed against the TNF receptor gene located within  
245 the 5' and 3' terminal repeats of the virus, named G2R\_NML. The previously published  
246 G2R\_WA assay targets this same loci<sup>18</sup> and indeed the reverse primer of the  
247 G2R\_NML and the forward primer of the G2R\_WA overlap. Figure 2a and 2b depict  
248 alignments of all of these assays' primer and probe sequences against a panel of Clade  
249 2 genomes drawn from recently sequenced genomes of the 2022 outbreak. Seven  
250 nucleotides of the 5' probe of the previously published G2R\_WA assay are non-  
251 complementary when aligned to a panel of Clade 1 genomes, as this design feature  
252 affords the discriminatory ability of this assay against Clade 1 and Clade 2 variants  
253 (Figure 2C). Figure 2d shows the alignment of the G2R\_G assay against Clade 1  
254 genomes, which shows its ability to also detect this MPXV clade. The amplicon sizes of  
255 the G2R\_NML and G2R\_WA assays are 136bp and 85bp, respectively (Table 1). The  
256 G2R\_G assay from Li *et al* (18), which can detect both clade 1 and 2 variants, was also  
257 employed in this work.

258 The log-linear slope, intercept, linear correlation, and PCR efficiencies of all of  
259 the above assays is described in Table 3. The slopes for each assay ranged from -3.43  
260 to -3.55, and delivered PCR efficiencies of 91% to 96%. The correlation coefficient  
261 across all assays ranged from 0.9956 to 0.9976. Intercepts across all assays ranged  
262 between 37.30 and 38.13, and none of the no-template control runs for each assay  
263 registered as positive.

264 The ALOD (95% CI) for the G2R\_G, G2R\_WA and G2R\_NML assays were 3.52 (2.47,  
265 6.03), 3.47 (2.37, 6.28) and 3.48 (2.42, 6.03) cp/rxn, respectively (see Figure 3A-C,  
266 vertical black line). This very closely matches what Li *et al*<sup>18</sup> found in their study where  
267 they report LOD values of ~3.5 and ~8.2 genomes from the G2R\_G and G2R\_WA  
268 assays, respectively. This implies a SLOD (95% CI) for the G2R\_G, G2R\_WA and

269 G2R\_NML assays were 0.55 (0.39, 0.94), 0.54 (0.37, 0.98) and 0.54 (0.38, 0.94) cp/mL.  
270 The ALOQ for the G2R\_G, G2R\_WA and G2R\_NML assays were 17.2, 19.9 and 20.1  
271 cp/rxn, respectively (see Figure 3D-F, vertical black line). The SLOQ for the G2R\_G,  
272 G2R\_WA and G2R\_NML assays were 2.68, 3.11 and 3.14 cp/mL.

273 For each assay, triplicates from qPCR positive wastewater samples were pooled and  
274 Sanger sequenced, then aligned to Monkeypox via BLAST analysis. The sequence  
275 confirmation rates for the G2R\_G, G2R\_WA, and G2R\_NML assays were 16%, 22%,  
276 and 76%, respectively ( $X^2$  p-value = 89.9 ( $3.07 \times 10^{-20}$ ), Table 4). Negative result  
277 denotes a false positive or a sequence fail.

278 The viral load from wastewater samples drawn from all communities tested in this work  
279 were determined using the G2R\_G, G2R\_WA and G2R\_NML assays in triplicate. The  
280 distribution of the censored geometric mean of replicate viral loads for all samples  
281 collected from July 7<sup>th</sup> to August 25<sup>th</sup> is presented in Figure 4A-left. The sample mean  
282 for the G2R\_G, G2R\_WA and G2R\_NML assays were 0.52, 0.45, and 0.51 cp/mL,  
283 respectively. These values were supported by Ct values of 36.3, 36.1 and 35.6 for the  
284 G2R\_G, G2R\_WA and G2R\_NML assays, respectively (Figure 4A-right). Spearman's  
285 correlations and a pair-wise comparison for all assays is presented in Figure 4 B-D.  
286 The correlations were as follows G2R\_WA:G2R\_NML was 0.717, G2R\_G:G2R\_WA  
287 was 0.754, and G2R\_G:G2R\_NML was 0.755.

288 All positive samples were submitted for Sanger sequencing. As described in Table 4,  
289 the % positivity rate for G2R\_G, G2R\_WA and G2R\_NML, was 16%, 28% and 76%.

290 Comparison of assay positivity across all three assays across all sites tested during the  
291 study period are represented in Figure 5. A major metropolitan center in nearly each  
292 Canadian province was tested over the 14 week study period. For one province, two  
293 city sites were tested (Figure 5 – "Province D"). If any wastewater treatment plant  
294 registered as positive for the week in a province, the entire week was marked as  
295 positive (Figure 5 – red boxes). For 5 provinces the first clinical detection was outside  
296 the study period for this work. For provinces D and H wastewater detection of MPXV  
297 was 7 and 3 weeks prior to clinical detection, respectively. For province G and I

298 wastewater detection of MPXV was 5 and 1 weeks following the first clinical detection,  
299 respectively.

300

## 301 **Discussion**

302

303           Currently, information on the fecal shedding of MPXV is limited. Adler *et al* have  
304 shown that MPXV DNA can be found in the upper respiratory tract, blood and urine of  
305 infected patients<sup>10</sup>, while Antinori *et al* have shown that MPXV DNA can be found in  
306 seminal fluid and feces as well<sup>11</sup>. Its widespread bodily secretion and excretion suggest  
307 the possibility that this virus can be tracked using WBS. With limited capacity for clinical  
308 testing and the stigma often associated with this illness, WBS can act as a  
309 complimentary surveillance tool not only to enhance surveillance efforts but also to  
310 provide a fulsome picture of the extent of MPX activity.

311           In this work, we demonstrate that the G2R\_NML assay is complementary to both  
312 G2R\_G and G2R\_WA from Li and co-workers<sup>18</sup> for detection of MPXV in wastewater.  
313 All assays have similar LODs and LOQs, and correlate well with each other as  
314 demonstrated by the high Spearman correlation. Most of the detections in this work  
315 were below the SLOD and SLOQ, despite a clear correlation across all assays. For this  
316 reason we favored interpretation of the data as a binary signal driven by assay  
317 positivity. MPXV wastewater signals were a leading indicator of reported clinical cases  
318 at the provincial level at provincial sites D and H and closely correlated with clinical  
319 detection at provincial site I. At provincial site G wastewater lagged considerably from  
320 clinical detection, although the lack of geo-location of clinical signal hampers precise  
321 interpretation. These data could be supportive of informing the allocation of resources  
322 such as vaccines to vulnerable populations with the areas of detection.

323           The specific advantage of NML-developed assay is that amplicons are more easily  
324 confirmed by Sanger sequencing. Likely, because the design of this assay has a  
325 slightly larger amplicon (136 vs 85/90 bp). This increase does not impact the qPCR  
326 efficiency, and the ALOD and ALOQ are comparable to the CDC assays. Amplicons

327 derived from environmental surveillance are a challenge to sequence due to the high-  
328 diversity of DNA in samples, which can lead to off-target amplification that inhibit  
329 sequencing efforts. This is made doubly difficult as signals tend to be at the technical  
330 limitations of qPCR. Sub-cloning amplicons is a viable but cumbersome route to  
331 garnering sequence confirmation. Since the current Monkeypox outbreak is an  
332 emerging and high-consequence issue for public health decision makers, timely access  
333 to sequence confirmation of emerging signals promotes uptake of this novel data  
334 stream. A recent study conducted by de Jonge *et al*<sup>28</sup> describes an elegant approach to  
335 confirm the qPCR signals obtained from MPXV detection in wastewater. In brief, a  
336 semi-nested qPCR was used to generate amplicons using the forward primer of the  
337 G2R\_G and the reverse primer of the G2R\_WA assays. The product was then put  
338 through another round of amplification using the G2R\_G probe and G2R\_WA reverse  
339 primer to generate an amplicon that could be Sanger sequenced<sup>28</sup>. Additionally, the  
340 distribution of Cts for the G2R\_NML assay is lower than the G2R\_G and G2R\_WA  
341 assays, suggesting that the performance of this assay is at least sensitive and perhaps  
342 more sensitive than the above mentioned assays. In sum, we feel that the G2R\_NML  
343 assay can act as a complement to developing MPXV wastewater surveillance systems.

344

345 Finally, for COVID-19 WBS, many groups include two targets as part of their assay  
346 regiment to mitigate the inherent variable nature of WBS and the risk of mutation.  
347 Given that there are indications that the recent Monkeypox outbreak could be driven in-  
348 part by a higher mutational frequency<sup>12</sup>, a second assay as part of a WBS surveillance  
349 program is a means to mitigating loss of sensitivity due to mutation. The CDC assays  
350 afford high sensitivity, yet the route to confirmation has proven challenging. The  
351 G2R\_NML assay could be a useful tool when this confirmation is required.

352 The Boehm group and others<sup>29,30</sup> have been advocates for WBS assay designs that  
353 extract genetic material from either the settled solids from primary influent/raw sewage  
354 or through high-solids samples sampled from the primary clarifier. The high prevalence  
355 and attack rate of SARS-CoV-2 have likely allowed for smaller process volumes to  
356 support COVID-19 surveillance that is minimally tracking clinical cases and

357 hospitalizations. However, the current MPXV outbreak shows that higher process  
358 volumes that are directed to the insoluble fractions are an operational necessity. To re-  
359 orient WBS systems to the process of high-solids contents is difficult as larger sample  
360 volumes are required to garner adequate material for processing, which can complicate  
361 sample collection, increase overhead of laboratory management and reduce throughput  
362 over smaller sample volumes. Standard methods to concentrate solid material at the  
363 point of sampling are a potential solution to alleviate the logistical burden of shipping  
364 large volumes of wastewater to support a central-laboratory model of WS.

365 To further develop MPXV WBS, several open questions should be answered; the  
366 stability of the virus across temperature and time should be performed, as it was for  
367 SARS-CoV-2. This will help define hold-times that ultimately limit/define the  
368 surveillance structure. Furthermore, an epidemiological useful scheme to track the  
369 mutations profile through metagenomics-like methods is required. As MPXV is a large  
370 virus this will likely be an onerous task. However, focusing on the immunologically  
371 relevant regions may be a route to an efficient and informative design, this is supported  
372 by observations that a signature change in MPXV genome over this recent outbreak  
373 have been changes to surface antigens present in the virus.

374 Future work to test the stability of the virus in wastewater is still required. Additionally,  
375 while we made every attempt to make the G2R\_NML assay specific to MPXV by in  
376 silico analysis, cross-reactivity studies involving other orthopoxvirus targets are still  
377 required. Also, further comparisons between clinical and wastewater signal trends are  
378 needed. Correspondence to clinical surveillance would be useful in further establishing  
379 the confidence of this assay, however, stigmatization could erode this correspondence.  
380 Case reported dates may be temporally separated from peak fecal shedding which is  
381 likely at the onset of symptomology. This necessitates careful follow-up studies as  
382 correspondence between clinical and wastewater signals requires both a temporal and  
383 spatial element.

384 The WBS for MPXV will enable jurisdictions to monitor the virus in their sewershed even  
385 when no clinical cases are known to be present. This will help make important resource  
386 allocation decisions in the current context when the system is overwhelmed with the

387 COVID-19 response. With no MPXV signal in wastewater, other public health priorities  
388 can be supported with more confidence.

### 389 **Conclusions**

390 The cause of the 2022 MPXV worldwide outbreak is not well understood. However, it  
391 highlights the fact that additional surveillance tools are necessary to better track and  
392 help contain its spread. This work suggests that WBS can be used as a viable  
393 surveillance strategy for the current MPXV outbreak.

### 394 **Acknowledgements**

395 We acknowledge the work of Jason Agasid for the quantification of the standard  
396 material. We acknowledge our collaboration with Statistics Canada for joint collection of  
397 wastewater through Canadian Wastewater Survey. We thank the municipalities for  
398 providing wastewater and participating Public Health authorities.

399

400

401

402

403 **Figures and Tables**

404

405 **Table 1:** G2R\_G, G2R\_WA, G2R\_NML primers and probes sequences, final  
 406 concentrations and amplicon lengths.

Target	Primer/probe	Sequence	Final Concentration (nM)	Amplicon size (bp)	Reference
G2R_G	F	GGAAAATGTAAAGACAACGAATACAG	400	90	Li et al. 2010
	R	GCTATCACATAATCTGGAAGCGTA	400		
	P	FAM-AAGCCGTAATCTATGTTGTCTATCGT-MGB	200		
G2R_WA	F	GGAAAATGTAAAGACAACGAATACAG	400	85	Li et al. 2010
	R	GCTATCACATAATCTGGAAGCGTA	400		
	P	FAM-AAGCCGTAATCTATGTTGTCTATCGT-MGB	200		
G2R_NML	F	AGGAGCATCAGGGTGTAGAA	400	136	In-house
	R	GGAAGAGACGGTGTGAGAATATG	400		
	P	FAM-CGTCATCTGTTCTCCGTGTGGTCC-MGB	200		

407

408

409

410 **Table 2:** MPXV 200bp DNA fragments for G2R\_G, G2R\_WA, and G2R\_NML targets.

Target(s)	Quantitation Standard Sequence
<b>G2R_G</b>	CTCGTATATATTGTTTCTCTCATGTATAATAATAAACGGAAGAGATATAGCACCACATGCACCATCCAA TGGAAGTGTAAAGACAACGAATACAGAAGCCGTAATCTATGTTGTCTATCGTGTCTCCGGAACTT ACGCTTCCAGATTATGTGATAGCAAGACTAATACACAATGTACACCGTGTGGTTCGGATACCT
<b>G2R_WA</b>	CGGATACACGTCTACCGGAGACGTCATCTGTTCTCCGTGTGGTCCCGGAACATATTCTCACACCGTCTC TTCCACAGATAAATGCGAACCCGTCGTAACCAGCAATACATTTAACTATATCGATGTGGAAATTAACCT GTATCCAGTCAACGACACATCGTGTACTCGGACGACCACTACCGGTCTCAGCGAATCCATCT
<b>G2R_NML</b>	GAATCTGTGAATGCTCTCCAGGATATTATTGTCTTCTCAAAGGAGCATCAGGGTGTAGAACATGTATT TCTAAAACAAAGTGTGGAATAGGATACGGAGTATCCGGATACACGTCTACCGGAGACGTCATCTGTTT TCCGTGTGGTCCCGGAACATATTCTCACACCGTCTCTTCCACAGATAAATGCGAACCCGTCGTA

411 **Table 3:** Real time qPCR assay parameters for G2R\_G, G2R\_WA, and G2R\_NML

Target	Slope	Intercept	RSQ	Efficiency
G2R_G	-3.55	38.13	0.9956	91%
G2R_WA	-3.49	37.62	0.9959	93%
G2R_NML	-3.43	37.30	0.9976	96%

412

413

414

415 **Table 4:** Proportion of positive real time qPCR signals that were confirmatory for MPXV

416 via Sanger sequence analysis.

Monkeypox Sequence Match	G2R_G (%)	G2R_WA (%)	G2R_NML (%)	$\chi^2$ (p-value)
Negative	82 (84)	98 (78)	27 (26)	89.9 (3.07×10 <sup>-20</sup> )
Positive	16 (16)	28 (22)	76 (74)	

417

418

419


420

421

422

423





424

425 **Figure 1 – Workflow to detect MPXV in wastewater.** Step 1 includes centrifuging 200 mL of sewage to  
426 obtain a solids pellet that is bead-beaten in a tube containing lysis buffer and silica-zirconium beads.

427 Step 2 depicts DNA isolation on the KingFisher Flex using the Qiagen MagAttract PowerMicrobiome kit.

428 Step 3 utilizes qPCR to detect and quantify MPXV targets. Following qPCR, the amplicons are Sanger

429 sequence confirmed.

430

431


432

433

434

435

It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).



436 **Figure 2 – Alignment of MPXV assay primers and probes to reference Clade two and Clade one strains.**


437 **A)** Alignment of the G2R\_NML, G2R\_WA and **B)** G2R\_G primers and probes to the TNF receptor gene

438 from reference Clade two MPXV genomes. **C)** Alignment of the G2R\_NML, G2R\_WA and **D)** G2R\_G

439 primers and probes to the TNF receptor genes from reference Clade one MPXV genomes. Identity graph  
440 illustrates pairwise-identity homology (green = match, light brown = mis-match). Purple graph illustrates  
441 the inverted terminal repeat (ITR) region. Image created using Geneious Prime® version 2022.0.2.


442

443



444 **Figure 3 – Limits of detection and quantification of G2R\_G, G2R\_NML, and G2R\_WA assays.**


445 **(A-C)** Positivity rates of the 3 assays obtained from a 15 serial dilution were fitted to a Probit regression  
446 for the estimation of the LoD (solid blue line). The 95% confidence interval from the regression fit (grey  
447 band) allows estimating the 95% confidence interval for the LoD (orange and purple dashed line). **(D-F)**  
448 Coefficient of variance of the 3 assays obtained from a 15 serial dilution were fitted to a linear  
449 regression for the estimation of the LoQ (solid blue line).



450

451 **Figure 4 – Performance of MPXV qPCR assays. (A-left)** Viral load distributions and supporting **(A-right)**  
452 Cts across the indicated assays for all communities tested is presented as a box and whisker box plot;  
453 the edges of the box of indicate the upper and lower quartiles, the whiskers extend to the values that  
454 are no further than 1.5 times the interquartile range, observations outside the whisker extent are  
455 represented by a dot. **(B-D)** Pair-wise comparison of log-transformed unadjusted viral loads for assays  
456 as indicated on the axes, non-detects are presented on their respective axis line. Spearman correlation  
457 for each pair-wise comparison are indicated above each plot.

458



459

460 **Figure 5 – Comparison of MPXV detections in wastewater across Canada and first clinical detections.**

461 Each row of the diagram represents surveillance in a major metropolitan centre for 9 Canadian  
462 provinces, except for province D where two cities represent the province. Each box in the matrix  
463 diagram represents a week of surveillance; for each week wastewater samples were tested across the  
464 three PCR assays described in this work, a positive detection by any assay is represented in red, a  
465 negative detections across all assays are represented in blue, and grey boxes indicate no sample was  
466 received from the site. The first clinical detection reported at the provincial for each site during the  
467 study period are indicated by a green box, where first clinical detection was outside the bounds of this  
468 work are indicated by a green circle to the left of the diagram.

469

470

## 471 References

472

- 473 (1) *WHO Director-General's statement at the press conference following IHR*  
474 *Emergency Committee regarding the multi-country outbreak of monkeypox - 23*  
475 *July 2022.* [https://www.who.int/news-room/speeches/item/who-director-general-s-](https://www.who.int/news-room/speeches/item/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi-country-outbreak-of-monkeypox--23-july-2022)  
476 [statement-on-the-press-conference-following-IHR-emergency-committee-](https://www.who.int/news-room/speeches/item/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi-country-outbreak-of-monkeypox--23-july-2022)  
477 [regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022](https://www.who.int/news-room/speeches/item/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi-country-outbreak-of-monkeypox--23-july-2022) (accessed  
478 2022-07-30).
- 479 (2) *2022 Monkeypox Outbreak Global Map | Monkeypox | Poxvirus | CDC.*  
480 <https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html>  
481 (accessed 2022-07-30).
- 482 (3) Magnus, P. von; Andersen, E. K.; Petersen, K. B.; Birch-Andersen, A. A POX-  
483 LIKE DISEASE IN CYNOMOLGUS MONKEYS. *Acta Pathol. Microbiol. Scand.*  
484 **1959**, 46 (2), 156–176. <https://doi.org/10.1111/J.1699-0463.1959.TB00328.X>.
- 485 (4) Ladnyj, I. D.; Ziegler, P.; Kima, E. A Human Infection Caused by Monkeypox Virus  
486 in Basankusu Territory, Democratic Republic of the Congo. *Bull. World Health*  
487 *Organ.* **1972**, 46 (5), 593.
- 488 (5) Marennikova, S. S.; Seluhina, E. M.; Mal'ceva, N. N.; Cimiskjan, K. L.; Macevic,  
489 G. R. Isolation and Properties of the Causal Agent of a New Variola-like Disease  
490 (Monkeypox) in Man. *Bull. World Health Organ.* **1972**, 46 (5), 599.
- 491 (6) Bunge, E. M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L. R.;  
492 Steffen, R. The Changing Epidemiology of Human Monkeypox—A Potential  
493 Threat? A Systematic Review. *PLoS Negl. Trop. Dis.* **2022**, 16 (2), e0010141.  
494 <https://doi.org/10.1371/JOURNAL.PNTD.0010141>.
- 495 (7) Prier, J. E.; Sauer, R. M. A POX DISEASE OF MONKEYS. *Ann. N. Y. Acad. Sci.*  
496 **1960**, 85 (3), 951–959. <https://doi.org/10.1111/J.1749-6632.1960.TB50015.X>.
- 497 (8) Shchelkunov, S. N. An Increasing Danger of Zoonotic Orthopoxvirus Infections.  
498 *PLOS Pathog.* **2013**, 9 (12), e1003756.  
499 <https://doi.org/10.1371/JOURNAL.PPAT.1003756>.

- 500 (9) Gong, Q.; Wang, C.; Chuai, X.; Chiu, S. Monkeypox Virus: A Re-Emergent Threat  
501 to Humans. *Viol. Sin.* **2022**. <https://doi.org/10.1016/J.VIRS.2022.07.006>.
- 502 (10) Adler, H.; Gould, S.; Hine, P.; Snell, L. B.; Wong, W.; Houlihan, C. F.; Osborne, J.  
503 C.; Rampling, T.; Beadsworth, M. B.; Duncan, C. J.; Dunning, J.; Fletcher, T. E.;  
504 Hunter, E. R.; Jacobs, M.; Khoo, S. H.; Newsholme, W.; Porter, D.; Porter, R. J.;  
505 Ratcliffe, L.; Schmid, M. L.; Semple, M. G.; Tunbridge, A. J.; Wingfield, T.; Price,  
506 N. M.; Abouyannis, M.; Al-Balushi, A.; Aston, S.; Ball, R.; Beeching, N. J.;  
507 Blanchard, T. J.; Carlin, F.; Davies, G.; Gillespie, A.; Hicks, S. R.; Hoyle, M.-C.;  
508 Ilozue, C.; Mair, L.; Marshall, S.; Neary, A.; Nsutebu, E.; Parker, S.; Ryan, H.;  
509 Turtle, L.; Smith, C.; van Aartsen, J.; Walker, N. F.; Woolley, S.; Chawla, A.; Hart,  
510 I.; Smielewska, A.; Joekes, E.; Benson, C.; Brindley, C.; Das, U.; Eyton-Chong, C.  
511 K.; Gnanalingham, C.; Halfhide, C.; Larru, B.; Mayell, S.; McBride, J.; Oliver, C.;  
512 Paul, P.; Riordan, A.; Sridhar, L.; Storey, M.; Abdul, A.; Abrahamsen, J.; Athan,  
513 B.; Bhagani, S.; Brown, C. S.; Carpenter, O.; Cropley, I.; Frost, K.; Hopkins, S.;  
514 Joyce, J.; Lamb, L.; Lyons, A.; Mahungu, T.; Mephram, S.; Mukwaira, E.; Rodger,  
515 A.; Taylor, C.; Warren, S.; Williams, A.; Levitt, D.; Allen, D.; Dixon, J.; Evans, A.;  
516 McNicholas, P.; Payne, B.; Price, D. A.; Schwab, U.; Sykes, A.; Taha, Y.; Ward,  
517 M.; Emonts, M.; Owens, S.; Botgros, A.; Douthwaite, S. T.; Goodman, A.; Luintel,  
518 A.; MacMahon, E.; Nebbia, G.; O'Hara, G.; Parsons, J.; Sen, A.; Stevenson, D.;  
519 Sullivan, T.; Taj, U.; van Nipsen tot Pannerden, C.; Winslow, H.; Zatyka, E.;  
520 Alozie-Otuka, E.; Beviz, C.; Ceesay, Y.; Gargee, L.; Kabia, M.; Mitchell, H.;  
521 Perkins, S.; Sasson, M.; Sehmbey, K.; Tabios, F.; Wigglesworth, N.; Aarons, E.  
522 J.; Brooks, T.; Dryden, M.; Furneaux, J.; Gibney, B.; Small, J.; Truelove, E.;  
523 Warrell, C. E.; Firth, R.; Hobson, G.; Johnson, C.; Dewynter, A.; Nixon, S.;  
524 Spence, O.; Bugert, J. J.; Hruby, D. E. Clinical Features and Management of  
525 Human Monkeypox: A Retrospective Observational Study in the UK. *Lancet*  
526 *Infect. Dis.* **2022**, 22 (8), 1153–1162. [https://doi.org/10.1016/S1473-](https://doi.org/10.1016/S1473-3099(22)00228-6)  
527 [3099\(22\)00228-6](https://doi.org/10.1016/S1473-3099(22)00228-6).
- 528 (11) Peiró-Mestres, A.; Fuertes, I.; Camprubí-Ferrer, D.; Marcos, M. Á.; Vilella, A.;  
529 Navarro, M.; Rodriguez-Elena, L.; Riera, J.; Català, A.; Martínez, M. J.; Blanco, J.



- 530 L.; Group, on behalf of the H. C. de B. M. S. Frequent Detection of Monkeypox  
531 Virus DNA in Saliva, Semen, and Other Clinical Samples from 12 Patients,  
532 Barcelona, Spain, May to June 2022. *Eurosurveillance* **2022**, 27 (28), 1.  
533 <https://doi.org/10.2807/1560-7917.ES.2022.27.28.2200503>.
- 534 (12) Isidro, J.; Borges, V.; Pinto, M.; Sobral, D.; Santos, J. D.; Nunes, A.; Mixão, V.;  
535 Ferreira, R.; Santos, D.; Duarte, S.; Vieira, L.; Borrego, M. J.; Nuncio, S.; de  
536 Carvalho, I. L.; Pelerito, A.; Cordeiro, R.; Gomes, J. P. Phylogenomic  
537 Characterization and Signs of Microevolution in the 2022 Multi-Country Outbreak  
538 of Monkeypox Virus. *Nat. Med.* **2022**. [https://doi.org/10.1038/S41591-022-01907-](https://doi.org/10.1038/S41591-022-01907-Y)  
539 [Y](https://doi.org/10.1038/S41591-022-01907-Y).
- 540 (13) Luna, N.; Ramírez, A. L.; Muñoz, M.; Ballesteros, N.; Patiño, L. H.; Castañeda, S.  
541 A.; Bonilla-Aldana, D. K.; Paniz-Mondolfi, A.; Ramírez, J. D. Phylogenomic  
542 Analysis of the Monkeypox Virus (MPXV) 2022 Outbreak: Emergence of a Novel  
543 Viral Lineage? *Travel Med. Infect. Dis.* **2022**, 49, 102402.  
544 <https://doi.org/10.1016/J.TMAID.2022.102402>.
- 545 (14) Xing, Y. H.; Ni, W.; Wu, Q.; Li, W. J.; Li, G. J.; Wang, W. Di; Tong, J. N.; Song, X.  
546 F.; Wing-Kin Wong, G.; Xing, Q. S. Prolonged Viral Shedding in Feces of  
547 Pediatric Patients with Coronavirus Disease 2019. *Journal of Microbiology,*  
548 *Immunology and Infection.* Elsevier Ltd 2020.  
549 <https://doi.org/10.1016/j.jmii.2020.03.021>.
- 550 (15) Di Giulio, D. B.; Eckburg, P. B. Human Monkeypox: An Emerging Zoonosis.  
551 *Lancet Infect. Dis.* **2004**, 4 (1), 15–25. [https://doi.org/10.1016/S1473-](https://doi.org/10.1016/S1473-3099(03)00856-9)  
552 [3099\(03\)00856-9](https://doi.org/10.1016/S1473-3099(03)00856-9).
- 553 (16) Li, Y.; Olson, V. A.; Laue, T.; Laker, M. T.; Damon, I. K. Detection of Monkeypox  
554 Virus with Real-Time PCR Assays. *J. Clin. Virol.* **2006**, 36 (3), 194–203.  
555 <https://doi.org/10.1016/J.JCV.2006.03.012>.
- 556 (17) Maksyutov, R. A.; Gavrilova, E. V.; Shchelkunov, S. N. Species-Specific  
557 Differentiation of Variola, Monkeypox, and Varicella-Zoster Viruses by Multiplex  
558 Real-Time PCR Assay. *J. Virol. Methods* **2016**, 236, 215–220.

- 559 <https://doi.org/10.1016/J.JVIROMET.2016.07.024>.
- 560 (18) Li, Y.; Zhao, H.; Wilkins, K.; Hughes, C.; Damon, I. K. Real-Time PCR Assays for  
561 the Specific Detection of Monkeypox Virus West African and Congo Basin Strain  
562 DNA. *J. Virol. Methods* **2010**, *169* (1), 223–227.  
563 <https://doi.org/10.1016/J.JVIROMET.2010.07.012>.
- 564 (19) Schroeder, K.; Nitsche, A. Multicolour, Multiplex Real-Time PCR Assay for the  
565 Detection of Human-Pathogenic Poxviruses. *Mol. Cell. Probes* **2010**, *24* (2), 110–  
566 113. <https://doi.org/10.1016/J.MCP.2009.10.008>.
- 567 (20) Kulesh, D. A.; Loveless, B. M.; Norwood, D.; Garrison, J.; Whitehouse, C. A.;  
568 Hartmann, C.; Mucker, E.; Miller, D.; Wasieloski, L. P.; Huggins, J.; Huhn, G.;  
569 Miser, L. L.; Imig, C.; Martinez, M.; Larsen, T.; Rossi, C. A.; Ludwig, G. V.  
570 Monkeypox Virus Detection in Rodents Using Real-Time 3'-Minor Groove Binder  
571 TaqMan Assays on the Roche LightCycler. *Lab. Invest.* **2004**, *84* (9), 1200–1208.  
572 <https://doi.org/10.1038/LABINVEST.3700143>.
- 573 (21) Selb, R.; Werber, D.; Falkenhorst, G.; Steffen, G.; Lachmann, R.; Ruscher, C.;  
574 McFarland, S.; Bartel, A.; Hemmers, L.; Koppe, U.; Stark, K.; Bremer, V.; Jansen,  
575 K.; group, on behalf of the B. M. study. A Shift from Travel-Associated Cases to  
576 Autochthonous Transmission with Berlin as Epicentre of the Monkeypox Outbreak  
577 in Germany, May to June 2022. *Eurosurveillance* **2022**, *27* (27), 2200499.  
578 <https://doi.org/10.2807/1560-7917.ES.2022.27.27.2200499>.
- 579 (22) Girometti, N.; Byrne, R.; Bracchi, M.; Heskin, J.; McOwan, A.; Tittle, V.; Gedela,  
580 K.; Scott, C.; Patel, S.; Gohil, J.; Nugent, D.; Suchak, T.; Dickinson, M.; Feeney,  
581 M.; Mora-Peris, B.; Stegmann, K.; Plaha, K.; Davies, G.; Moore, L. S. P.; Mughal,  
582 N.; Asboe, D.; Boffito, M.; Jones, R.; Whitlock, G. Demographic and Clinical  
583 Characteristics of Confirmed Human Monkeypox Virus Cases in Individuals  
584 Attending a Sexual Health Centre in London, UK: An Observational Analysis.  
585 *Lancet Infect. Dis.* **2022**. [https://doi.org/10.1016/S1473-3099\(22\)00411-X](https://doi.org/10.1016/S1473-3099(22)00411-X).
- 586 (23) Medema, G.; Heijnen, L.; Elsinga, G.; Italiaander, R.; Brouwer, A. Presence of  
587 SARS-Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19

- 588 Prevalence in the Early Stage of the Epidemic in the Netherlands. *Environ. Sci.*  
589 *Technol. Lett.* **2020**, 7 (7), 511–516.  
590 <https://doi.org/10.1021/ACS.ESTLETT.0C00357/ASSET/IMAGES/LARGE/EZ0C0>  
591 0357\_0002.JPEG.
- 592 (24) Kim, S.; Kennedy, L. C.; Wolfe, M. K.; Criddle, C. S.; Duong, D. H.; Topol, A.;  
593 White, B. J.; Kantor, R. S.; Nelson, K. L.; Steele, J. A.; Langlois, K.; Griffith, J. F.;  
594 Zimmer-Faust, A. G.; McLellan, S. L.; Schussman, M. K.; Ammerman, M.;  
595 Wigginton, K. R.; Bakker, K. M.; Boehm, A. B. SARS-CoV-2 RNA Is Enriched by  
596 Orders of Magnitude in Primary Settled Solids Relative to Liquid Wastewater at  
597 Publicly Owned Treatment Works. *Environ. Sci.* **2022**, 8 (4), 757.  
598 <https://doi.org/10.1039/D1EW00826A>.
- 599 (25) Tourlousse, D. M.; Narita, K.; Miura, T.; Sakamoto, M.; Ohashi, A.; Shiina, K.;  
600 Matsuda, M.; Miura, D.; Shimamura, M.; Ohyama, Y.; Yamazoe, A.; Uchino, Y.;  
601 Kameyama, K.; Arioka, S.; Kataoka, J.; Hisada, T.; Fujii, K.; Takahashi, S.;  
602 Kuroiwa, M.; Rokushima, M.; Nishiyama, M.; Tanaka, Y.; Fuchikami, T.; Aoki, H.;  
603 Kira, S.; Koyanagi, R.; Naito, T.; Nishiwaki, M.; Kumagai, H.; Konda, M.;  
604 Kasahara, K.; Ohkuma, M.; Kawasaki, H.; Sekiguchi, Y.; Terauchi, J. Validation  
605 and Standardization of DNA Extraction and Library Construction Methods for  
606 Metagenomics-Based Human Fecal Microbiome Measurements. *Microbiome*  
607 **2021**, 9 (1), 1–19. <https://doi.org/10.1186/S40168-021-01048-3/FIGURES/4>.
- 608 (26) Ahmed, W.; Bivins, A.; Metcalfe, S.; Smith, W. J. M.; Verbyla, M. E.; Symonds, E.  
609 M.; Simpson, S. L. Evaluation of Process Limit of Detection and Quantification  
610 Variation of SARS-CoV-2 RT-QPCR and RT-DPCR Assays for Wastewater  
611 Surveillance. *Water Res.* **2022**. <https://doi.org/10.1016/j.watres.2022.118132>.
- 612 (27) Agency, O. C. W. *The Protocol for Evaluations of RT-QPCR Performance*  
613 *Characteristics*; Chik, A. H. S., Ed.; 2022.
- 614 (28) de Jonge, E. F.; Peterse, C. M.; Koelewijn, J. M.; van der Drift, A. M. R.; van der  
615 Beek, R. F. H. J.; Nagelkerke, E.; Lodder, W. J. The Detection of Monkeypox  
616 Virus DNA in Wastewater Samples in the Netherlands. *Sci. Total Environ.* **2022**,

- 617 852, 158265. <https://doi.org/10.1016/J.SCITOTENV.2022.158265>.
- 618 (29) Peccia, J.; Zulli, A.; Brackney, D. E.; Grubaugh, N. D.; Kaplan, E. H.; Casanovas-  
619 Massana, A.; Ko, A. I.; Malik, A. A.; Wang, D.; Wang, M.; Warren, J. L.;  
620 Weinberger, D. M.; Arnold, W.; Omer, S. B. Measurement of SARS-CoV-2 RNA in  
621 Wastewater Tracks Community Infection Dynamics. *Nat. Biotechnol.* **2020**, *38*  
622 (10), 1164. <https://doi.org/10.1038/S41587-020-0684-Z>.
- 623 (30) D'Aoust, P. M.; Mercier, E.; Montpetit, D.; Jia, J. J.; Alexandrov, I.; Neault, N.;  
624 Baig, A. T.; Mayne, J.; Zhang, X.; Alain, T.; Langlois, M. A.; Servos, M. R.;  
625 MacKenzie, M.; Figeys, D.; MacKenzie, A. E.; Graber, T. E.; Delatolla, R.  
626 Quantitative Analysis of SARS-CoV-2 RNA from Wastewater Solids in  
627 Communities with Low COVID-19 Incidence and Prevalence. *Water Res.* **2021**,  
628 *188*, 116560. <https://doi.org/10.1016/J.WATRES.2020.116560>.
- 629
- 630
- 631
- 632

